We have a special assignment: your health
Vaccines improve the quality of life by preventing serious illnesses. They play a key role in promoting public health. We conduct reliable research on the quality, safety and efficacy of vaccines.
WHY FVR?
- Capability to enroll high volumes of participants for clinical trials (thousands) and large pragmatic trials (tens of thousands)
- Decades of vaccine study experience from >160 studies throughout all age groups
- Strong references for post-licensure studies, favourable Finnish operating-environment
- Core focus on vaccine trials
- Continuous development mindset, agility and drive to innovate together with partners
Key figures (year end 2023)
Our research expertise
We study vaccines with decades of experience and internationally recognized, high-quality scientific expertise. Our comprehensive network of clinics offers first-class prerequisites for this. We offer clinical expertise in phases 1-4 of vaccine research as well as investigations into the effectiveness and safety of vaccines already in use. We have strong expertise in Real-World Evidence (RWE) studies and pragmatic vaccine trials, utilizing Finland’s comprehensive health registers and data resources.
We promote science-based vaccination expertise and public acceptance in Finland and in the world by means of high-quality vaccine research.
Newsfeed
-
FVR grows its core capabilities in vaccine research
FVR – Finnish Vaccine Research Ltd, one of Europe’s leading commercial vaccine trial service providers, is growing its core competencies by hiring extensive industry and medical expertise. Santtu Heinonen appointedLead Medical ExpertMD, PhD, ORCID >> Santtu is a pediatrician, soon to finalize specialty in pediatric infectious diseases. He has more than 15 years of experience…
Research clinics
-
FVR, Espoo Clinic
-
FVR, Helsinki East Clinic
-
FVR, Helsinki South Clinic
-
FVR, Järvenpää Clinic
-
FVR, Kokkola Clinic
-
FVR, Oulu Clinic
-
FVR, Pori Clinic
-
FVR, Seinäjoki Clinic
-
FVR, Tampere Clinic
-
FVR, Turku Clinic
-
RWE-studies